LL-37 peptide​ Scientific Research

LL-37 and Inflammatory Diseases
LL-37 is frequently detected in inflamed tissues and has been evaluated in models of psoriasis, lupus, rheumatoid arthritis, atherosclerosis, and other immune-mediated conditions. Depending on the local environment, LL-37 has been observed to:

• Decrease keratinocyte apoptosis in certain skin models
• Increase interferon-alpha (IFN-α) production under specific stimulation conditions
• Influence chemotaxis of neutrophils and eosinophils
• Down-regulate toll-like receptor 4 (TLR4)–mediated signaling in selected systems
• Increase interleukin-18 (IL-18) production in some contexts
• Associate with reduced atherosclerotic plaque burden in certain experimental models

A notable feature is that LL-37 does not behave uniformly. For example, in T-cell research systems, LL-37 may enhance inflammatory actions when cells are not yet activated but may dampen inflammation once cells are already activated. This has led to the working hypothesis that LL-37 functions as a homeostatic modulator, helping fine-tune immune reactivity rather than driving a fixed pro- or anti-inflammatory outcome.

Antimicrobial Activity of LL-37
As part of the innate immune system, LL-37 is among the early-responding peptides during microbial challenge:

• Skin models: Baseline skin often shows low LL-37 levels, which can rise markedly upon exposure to microbial agents.
• Synergy with other peptides: LL-37 has been observed to act cooperatively with other endogenous peptides, such as human beta-defensin 2, in experimental infection models.
• LPS binding: LL-37 binds bacterial lipopolysaccharide (LPS), an essential component of gram-negative bacterial outer membranes, thereby disrupting microbial membrane integrity and contributing to direct antimicrobial effects.
• Gram-positive organisms: Despite its well-described interactions with LPS, LL-37 also demonstrates activity against gram-positive organisms and has been shown in vitro to enhance the effects of lysozyme against pathogens such as Staphylococcus aureus.

These properties make LL-37 a useful tool for studying multi-layered innate defense mechanisms in vitro and in vivo.

LL-37 and Lung Biology
In respiratory models, LL-37 has been studied in the context of airborne LPS exposure, toxic dust environments, and chronic airway disease:

• Epithelial response: LL-37 expression can increase in airway epithelial cells following exposure to irritants or microbial products.
• Wound closure and repair: Research indicates that LL-37 promotes airway epithelial cell migration and proliferation, supporting wound closure in in vitro and animal models.
• Angiogenesis and tissue homeostasis: LL-37 appears to contribute to coordinated repair responses by attracting structural cells and influencing local vasculature, underscoring its role as a potential homeostatic regulator in the airways.

These findings support the use of LL-37 as a model molecule for linking innate defense with epithelial repair in lung research.

LL-37 in Arthritis and Joint Inflammation
Elevated LL-37 levels have been reported in experimental models of joint inflammation, including those modeling rheumatoid arthritis:

• Presence in inflamed joints: LL-37 is detected in joint tissues and synovial fluid under inflammatory conditions, though current evidence does not support a direct pathogenic role.
• Protective hypotheses:
  • LL-37–derived peptides have been shown in animal models to protect against collagen damage and reduce disease severity scores in inflammatory arthritis research systems.
  • LL-37 has been associated with modulation of interleukin-32–driven inflammation, a cytokine linked to arthritis severity.
• Toll-like receptor pathways: LL-37 interacts with TLR pathways (e.g., TLR4), and ongoing work aims to clarify whether this interaction contributes to selective dampening of joint-destructive inflammatory responses.

Overall, LL-37 is being explored as a marker and potential modulator of inflammatory joint microenvironments rather than a primary cause of disease.

LL-37 and Intestinal Models
In gastrointestinal research, LL-37 has been evaluated for effects on epithelial barrier integrity, repair, and inflammation:

• Barrier maintenance: Cell culture studies show that LL-37 can enhance the migration of epithelial cells involved in maintaining the intestinal barrier.
• Apoptosis modulation: Under inflammatory conditions, LL-37 has been associated with reduced epithelial cell apoptosis, suggesting a possible protective effect on mucosal integrity.
• Combination with defensins: LL-37 appears to work alongside human beta-defensin 2 to promote wound closure and reduce TNF-related cell death in intestinal models.

These findings have led to interest in LL-37 as an experimental adjuvant in models of inflammatory bowel conditions, post-surgical healing, and antibiotic-associated gut injury—strictly at the research level.

LL-37, Cancer, and Blood Vessel Growth
The relationship between LL-37 and cancer is complex and context-dependent:

• Tumor microenvironment: In certain gastrointestinal and oral cancer models, LL-37 has been studied as part of vitamin D–responsive pathways in tumor-associated macrophages. These investigations look at how vitamin D–related signaling via LL-37 may influence local anti-tumor mechanisms.
• Angiogenesis: LL-37 can stimulate prostaglandin E2 (PGE2) production in endothelial cells, a mediator known to be involved in angiogenesis. This has implications for:
  • Modeling pro-angiogenic responses in wound healing and ischemic tissue
  • Exploring how altered angiogenesis may contribute to tumor growth or be targeted in cancer research

Through these lines of study, LL-37 is used as a tool to understand angiogenic control and the dual roles of inflammatory mediators in both repair and neoplastic processes.

Article Titles & Journals

• RNA selectively modulates activity of virulent amyloid PSMα3 and host-defense LL-37 via ph
• Interfacial activity and membrane interaction of Duttaphrynus melanostictus cathelicidin.

• NF-κB/AP-1-mediated expression of the porcine cathelicidin proPMAP-37 suppresses inflammat

• Functional diversity of cathelicidin peptides in the frog lung: An integrated transcriptom

• Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory r